Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.39) by 12.82 percent. This is a 20 percent increase over losses of $(0.55) per share from the same period last year. The company reported $209.00 thousand in sales this quarter.